MENLO PARK, Calif. and
SANTA CRUZ, Calif., Sept. 22, 2016 /PRNewswire/ -- Pacific
Biosciences of California, Inc.,
(Nasdaq:PACB), and Dovetail Genomics™ LLC
today announced that Dovetail has added PacBio®
SMRT® sequencing and de novo assembly options to
its menu of genome assembly services. The companies also announced
their signing of a co-marketing agreement under which the new
service offerings will be jointly promoted.
"We are impressed by Dovetail's continued commitment to deliver
the most comprehensive view of genomes," said Kevin Corcoran, Senior Vice President of Market
Development at Pacific Biosciences. "Until now, Dovetail has
focused exclusively on short-read NGS data, so we are pleased to
see the addition of our long-read SMRT Sequencing technology to
their service offering, and to partner with Dovetail to provide the
best possible genome assemblies to the scientific community."
"The addition of these services is in direct response to our
customers' needs," said Brandon
Rice, Dovetail Genomics' Chief Operations Officer, "so we
are excited to provide this option for our customers who need, or
simply prefer, a long-read sequencing approach for their genome
assembly projects."
PacBio SMRT Sequencing delivers long read lengths with high
consensus accuracy and uniform coverage, allowing scientists to go
beyond fragmented draft genomes and generate the most comprehensive
de novo assemblies. Dovetail found through its services
that its approach to scaffolding with Chicago™ libraries and
its HiRise™ scaffolding pipeline are highly
complementary to PacBio-based assemblies. This new offering is
especially valuable to scientists working on highly repetitive,
polyploid genomes that are challenging to resolve with short-read
sequencing alone.
The two companies will begin co-marketing the Dovetail service
offering immediately. Interested parties can learn more here.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers
sequencing systems to help scientists resolve genetically complex
problems. Based on its novel Single Molecule, Real-Time
(SMRT®) technology, Pacific Biosciences' products
enable: de novo genome assembly to finish genomes in order
to more fully identify, annotate and decipher genomic structures;
full-length transcript analysis to improve annotations in reference
genomes, characterize alternatively spliced isoforms in important
gene families, and find novel genes; targeted sequencing to more
comprehensively characterize genetic variations; and real-time
kinetic information for epigenome characterization. Pacific
Biosciences' technology provides high accuracy, ultra-long reads,
uniform coverage, and is the only DNA sequencing technology that
provides the ability to simultaneously detect epigenetic changes.
PacBio® sequencing systems, including consumables and
software, provide a simple, fast, end-to-end workflow for SMRT
Sequencing. More information is available at www.pacb.com.
About Dovetail Genomics
Dovetail Genomics LLC is transforming genomics by making
long-range information readily accessible to all. The company
enables researchers and clinicians to solve complex problems
involving de novo assembly, structural variation, microbiome
analysis, cancer research, phasing analysis and more by providing
them a more comprehensive view of the genome. Its proprietary in
vitro proximity ligation approach simplifies genomic discovery by
integrating the highest quality long-range genomic information with
next-gen sequencing output. Dovetail is based in Santa Cruz, California. For more information
on Dovetail, its technology and service offerings,
visit dovetailgenomics.com. Follow Dovetail on Twitter
@DTGenomics.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future availability, uses, quality or
performance of, or benefits of using, products or technologies,
expected benefits of the agreement between Pacific Biosciences and
Dovetail Genomics and other future events. You should not place
undue reliance on forward-looking statements because they involve
known and unknown risks, uncertainties, changes in circumstances
and other factors that are, in some cases, beyond Pacific
Biosciences' control and could cause actual results to differ
materially from the information expressed or implied by
forward-looking statements made in this press release. Factors that
could materially affect actual results can be found in Pacific
Biosciences' most recent filings with the Securities and
Exchange Commission, including Pacific Biosciences' most recent
reports on Forms 8-K, 10-K and 10-Q, and include those listed under
the caption "Risk Factors."
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dovetail-genomics-adds-pacbio-smrt-sequencing-and-assembly-to-its-services-menu-300332479.html
SOURCE Dovetail Genomics LLC; Pacific Biosciences of
California, Inc.